FREENOME PRESENTS A SUBJECT POPULATION ANALYSIS OF A CLINICAL STUDY USING A MULTIOMICS BLOOD TEST FOR THE EARLY DETECTION OF COLORECTAL CANCER
Today Freenome, a privately held biotech company, presents a subject population analysis from PREEMPT CRC, a study for the detection of colorectal cancer (CRC) at the Western Colorectal Cancer Consortium Conference in Portland, Oregon. The study's focus was to enroll subjects that reflected the demographics of the intended use population for a colorectal cancer screening test: average-risk adults between the ages of 45 and 85 across urban and rural communities in the United States. The company offered options of virtual enrollment, electronic consenting and mobile phlebotomy that enabled home blood draws for participants who were not geographically close or able to visit a hospital or other study site. Analysis of results demonstrate enrollment strategies were effective in recruiting an intended-use population. Freenome is in the final stages of development of its blood-based screening test for colorectal cancer. The test uses Freenome's multiomics platform, which combines tumor and non-tumor signals with machine learning to detect cancer in the earliest, most treatable stages using a standard blood draw. The test is intended to offer an accessible and convenient option for CRC screening.
#ml
#software
#platform